TXN and hepatocellular carcinoma: A comparison of the Sorafenib and Trx1 silencing targets of each cell line (Figure 4C) highlighted the fact that there were no common targets between the se cell lines, suggesting that the effects of each treatment are dependent on the de-differentiation stage of HCC cell lines.